US 12,291,565 B2
Tau binding compounds
Wencheng Liu, Cambridge, MA (US); Todd Carter, Winchester, MA (US); Ishan Sanjeev Shah, Andover, MA (US); Christopher Joseph Murray, Poleglass (IE); James Bernard McClory, Ballynaskeagh (IE); and Dinah Wen-Yee Sah, Hopkinton, MA (US)
Assigned to VOYAGER THERAPEUTICS, INC., Lexington, MA (US)
Filed by VOYAGER THERAPEUTICS, INC., Lexington, MA (US)
Filed on Jun. 5, 2024, as Appl. No. 18/734,892.
Application 18/734,892 is a continuation of application No. PCT/US2023/074239, filed on Sep. 14, 2023.
Claims priority of provisional application 63/448,913, filed on Feb. 28, 2023.
Claims priority of provisional application 63/406,924, filed on Sep. 15, 2022.
Prior Publication US 2024/0391988 A1, Nov. 28, 2024
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61P 25/28 (2006.01); C12N 15/86 (2006.01)
CPC C07K 16/18 (2013.01) [A61P 25/28 (2018.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C12N 2750/14143 (2013.01)] 28 Claims
 
1. An antibody that binds to human tau, which comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO: 1144, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 1145, and a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 410; and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO: 1146, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 529, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 571; and wherein:
(i) the VH comprises the amino acid V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; S at position 14; A at position 16; K at position 19; V at position 20; R at position 38; Q at position 39; A at position 40; Q at position 43; R at position 67; V at position 68; I at position 71; R at position 72; D at position 73; T at position 74; T at position 76; T at position 84; and L at position 113, numbered according to SEQ ID NO: 21; and
(ii) the VL comprises the amino acid I at position 2; S at position 7; S at position 12; T at position 14; P at position 15; Q at position 17; P at position 18; Q at position 50; S at position 68; V at position 88; Y at position 92; Q at position 105; and V at position 109, numbered according to SEQ ID NO: 93.